^
    Back
    Association details:
    Biomarker:RICTOR amplification
    Cancer:Small Cell Lung Cancer
    Drug:vistusertib (AZD2014) (mTOR inhibitor, mTORC2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification

    Excerpt:
    ...- Small cell lung cancer harboring RICTOR amplification...
    Trial ID:
    SUKSES-D
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Oncotarget
    Title:

    RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR

    Excerpt:
    In parallel, cells with RICTOR copy number (CN) gain showed increased sensitivity to three mTOR inhibitors, AZD8055, AZD2014 and INK128 in cell growth assays, with AZD2014 demonstrating the best inhibition of downstream signaling.
    DOI:
    10.18632/oncotarget.13362